Evidence map›Paper›PMID 42449619›Full record

ArticleCancers2026

Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.

Marc-Oliver Grimm, Viktor Grünwald, Harald Müller-Huesmann, Philipp Ivanyi, Martin Schostak, Eyck von der Heyde, Wolfgang Schultze-Seemann, Holger Schulz, Martin Bögemann, Stefan Wolfgang Grötzinger and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marc-Oliver GrimmDepartment of Urology, Jena University Hospital, Friedrich-Schiller University Jena, 07747 Jena, Germany.ORCID 0000-0003-3084-8654
Viktor GrünwaldClinic for Medical Oncology and Clinic for Urology, West-German Cancer Center Essen, Essen University Hospital, 45147 Essen, Germany.ORCID 0000-0003-2083-7687
Harald Müller-HuesmannDepartment of Internal Medicine, Hematology and Oncology, St Josef Brothers Hospital, 33098 Paderborn, Germany.
Philipp IvanyiClinic Department of for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Interdisciplinary Oncologic Outpatient Clinic (OIA), Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-2862-7302
Martin SchostakLOGICURO GmbH, 14482 Potsdam-Babelsberg, Germany.ORCID 0000-0002-8717-2096
Eyck von der HeydePractice for Oncology Raschplatz, 30161 Hannover, Germany.
Wolfgang Schultze-SeemannDepartment of Urology, Freiburg University Hospital, 79106 Freiburg, Germany.
Holger SchulzPractice for Medical Oncology and Hematology, 50226 Frechen, Germany.
Martin BögemannDepartment of Urology, Münster University Hospital, 48149 Münster, Germany.ORCID 0000-0002-2569-4446
Stefan Wolfgang GrötzingerBristol Myers Squibb Germany, 80636 Munich, Germany.
Luis VazBristol Myers Squibb UK, Uxbridge UB11 1AF, UK.ORCID 0000-0002-2184-1234
Martin HerberBristol Myers Squibb Germany, 80636 Munich, Germany.
Jens BedkeDepartment of Urology and Transplant Surgery, Stuttgart Hospital, 70174 Stuttgart, Germany.

Funding

Bristol Myers Squibb n.a.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

effectivenessimmunotherapynivolumabreal-world datasafety

Identifiers

PMID42449619
PMCPMC13359622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.